View Older Stories View More Recent Stories
-
EVS to Present at the 27th Annual Roth Conference
-
Uranium Resources (URRE) Enters 4M Common Stock, 2M Warrants Placement
-
Alcobra Ltd. to Present at 27th Annual ROTH Conference
-
MacroGenics to Present at the Roth Capital Partners 27th Annual Growth Stock Conference
-
Curis Announces Closing of Public Offering of Common Stock
-
Roth Capital Positive on Ligand Pharma (LGND); Kyprolis Met Primary Endpoint in ENDEAVOR Trial (AMGN)
-
Burcon to Present at the 27th Annual ROTH Conference on March 10, 2015
-
UBL Interactive to Present at 27th Annual ROTH Conference on March 9, 2015
-
Roth Capital Lowers FY15 Revs, GM Outlook on Ballard Power (BLDP); Maintains 'Buy' Rating
-
Celldex Announces Exercise of Underwriters' Option to Purchase Additional Shares
-
Roth Capital Downgrades Clayton Williams Energy (CWEI) to Neutral
-
I.D. Systems to Present at 27th Annual ROTH Conference on March 10, 2015
-
Roth Capital Trims PT on Keryx Biopharma (KERX) to $27; 'Blocking and Tacking' w/ Medicare to Ensure Auryxia Success
-
MoSys (MOSY) Prices 12.5M Common Offering at $1.60/Share
-
MoSys (MOSY) Poised to Open Lower Following Stock Offering
-
Roth Capital (SPPI) Comments on Spectrum (SPPI) Following Tentative FDA Approval of Sandoz's Levoleucovorin Calcium
-
Roth Positive on Expansion of STAR Study Sites; Afforms Cytori (CYTX) at 'Buy'
-
Notable Analyst Rating Changes 2/26: (AXP) (TMUS) (JAKK) Upgraded; (PCRX) (CVC) (PGRE) Downgraded
-
Pre-Open Stock Movers 02/26: (ELX) (CYBX) (UIL) (CRM) Higher; (CLRX) (LKQ) (TASR) Lower (more...)
-
Landec to Present at the 27th Annual ROTH Conference on March 10, 2015
-
Profire Energy to Present at 27th Annual ROTH Conference on March 10, 2015
-
Lion Biotechnologies (LBIO) Prices 8M Common Offering at $8/Share
-
Roth Capital Starts Ohr Pharmaceutical (OHRP) at Buy
-
Celldex Therapeutics Prices Public Offering of Common Stock
-
Roth Tweaks Numbers on Auryxia Ahead of Keryx Pharna's (KERX) Q4 Report; Maintains 'Buy' Rating
-
Upcoming Milestones, Key Investment Points for Bio Blast Pharma (ORPN) Being Missed by Investors - Roth Capital
-
Curis (CRIS) Prices 21.8M Common Offering at $2.75/Share
-
Curis Prices Public Offering of Common Stock
-
Curis Reports Fourth Quarter and Year-End 2014 Financial Results
-
Revolution Lighting Technologies to Present at 27th Annual ROTH Conference
-
Notable Analyst Rating Changes 2/23: (LH) (PENN) (CL) Upgraded; (BA) (RIG) (DGX) Downgraded
-
Breakthrough Designation for Celldex's (CLDX) Rintega Points to Stronger FDA Support as Cancer Vaccine in GBM - Roth Capital
-
Roth Capital Upgrades New Gold (NGD) to Neutral
-
Roth Capital Starts Flex Pharma (FLKS) at Buy
-
Roth Capital Starts Zosano Pharma (ZSAN) at Buy
-
Roth Capital Downgrades Spectrum Pharmaceuticals (SPPI) to Neutral
-
Notable Analyst Rating Changes 2/20: (MRVL) (DSW) (KN) Upgraded; (FUEL) (HLSS) (REGN) Downgraded
-
Roth Capital Downgrades Regeneron (REGN) to Neutral; Pipeline Opportunities Largely Priced In
-
Notable Analyst Rating Changes 2/19: (COH) (VLO) (MWW) Upgraded; (I) (PCYC) (HUN) Downgraded
-
Pre-Open Stock Movers 02/19: (BJRI) (PCLN) (BBW) Higher; (OCRX) (NLST) (CSLT) Lower (more...)
-
UPDATE: Roth Capital Cuts Pharmacyclics (PCYC) to Neutral; Sees FY15 Guidance, Market Expectations Priced into Shares
-
SolarCity (SCTY) May See N-T Weakness on Unfavorable Mix; Roth Maintains 'Buy' Rating
-
Roth Capital Starts Spark Therapeutics (ONCE) at Buy
-
ZAGG Inc to Present at 27th Annual Roth Conference
-
Hill International to Present at the 27th Annual ROTH Conference
-
Roth Capital Boosts Ests on Enphase (ENPH) Following Q4 Numbers, Outlook
-
Roth Affirms Bio Blast Pharma (ORPN) at 'Buy'; Plenty of Catalysts Ahead in Next 12 - 18 Months
-
Roth Still Positive on Cytori (CYTX) as ACT-OA Phase 2 Commences
-
Edgewater to Present at the 27th Annual ROTH Conference on March 10, 2015
-
Palatin (PTN) Outpaces Q2 Ests on BMT Program Milestone; Roth Capital Affirms at 'Buy'

